Zhijian Xiao

ORCID: 0000-0002-1099-4489 · 2 papers in corpus

article 2022

Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study

·doi:10.1002/hon.3026

Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…

article 2014

[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].

·doi:10.3760/cma.j.issn.0253-2727.2014.08.006

OBJECTIVE: To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia. METHODS: A cohort of 58 PMF patients with anemia …